Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 12

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 12
---
 product revenue to $268.4 million, 
 representing a 26% increase compared to 2023 and another all-time high for the brand.                                             |

| 3 |

Advance our Differentiated Pipeline Programs into Clinical Trial Initiations and Data Readouts

| • | Our shingles vaccine program, Z-1018, is an investigational vaccine candidate being developed for the prevention                             
 of shingles in adults aged 50 and older. In June 2024, we initiated a Phase 1/2 clinical trial evaluating the safety, tolerability,          
 and immunogenicity of Z-1018. Enrollment in the Phase 1/2 randomized, active-controlled, dose escalation, multicenter trial was completed    
 in 2024, with approximately 440 healthy adults aged 50 to 69 years enrolled at trial sites in Australia. The trial will evaluate             
 the safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix. Key objectives of the trial include selecting the optimal       
 glycoprotein E (gE) protein dose level and dosing schedule for further clinical development. We anticipate reporting top line immunogenicity 
 and safety data from this trial in the third quarter of 2025.                                                                                |
| • | We are developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018 adjuvant, in collaboration with, and fully funded               
 by, the U.S. Department of Defense (“DoD”). In late 2024, we completed a Phase 2 clinical trial evaluating the immunogenicity,               
 safety, and tolerability in adults of a plague (rF1V) vaccine candidate adjuvanted with CpG 1018. Based on the results from that             
 study, we executed a new agreement with the DoD for approximately $30 million through the first half of 2027 to support additional           
 Phase 2 clinical and manufacturing activities.                                                                                               |

| 4 |

<div align='center'>Executive Compensation Highlights</div>

We believe that compensation should align
our executives’ interests with that of our stockholders over the long-term through achievement of strategic corporate
objectives that are fundamental to our business and that are intended to create long-term stockholder value. Our executive
compensation programs are designed to be competitive within our industry and within our peer group to enable us to attract,
motivate, reward, and retain outstanding talent. The following executive compensation practices and policies have been
adopted by the Compensation Committee